microdose glp-1 noom launches Proactive Health Program for long-term health Noom Unveils Microdose GLP-1 Program

Drucker is professor of Medicine in the Division of Endocrinology at the University of Toronto and holds the Banting and Best Diabetes Centre-Novodisk Chair in Incretin Biology

Its anorexigenic and insulinotropic action make GLP-1 an appealing candidate for the treatment of obesity and diabetes

,

BrightonCARievajJKuhreREGlassLLSchoonjansKHolstJJet al

Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney disease [8]